Finzati - Logo
ANAB logo

AnaptysBio, Inc.

ANAB • Biotechnology
$45.43
▼ -3.81 (-7.74%)
Current price
EarningsLatest report: Jun 30, 2026
BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$1.64B
Growth
4.6%
Cash Flow
1/5
Trend
Volatile
Evidence
Stable or improving margins · -5.6%Positive revenue growth · 38.4%Positive free cash flow · 0.71Manageable debt level · 0.38Healthy liquidity · 9.07
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Sep 25, 2026, 12:06 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$45.43
Change-7.74%
Shares Out35.98M
Market Cap$1.64B
Enterprise Value$1.49B
52W Range13.86 - 72.36
Beta0.41
P/E8.40
P/S6.92
P/B155.29
P/FCF90.97
EV/Sales6.28

Investment DNA

How strong this company looks for long-term investors

58
out of 100
Business Quality
Margins, moat, returns
43/100
Financial Strength
Debt, cash, stability
75/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
46/100
Why this score▼
Stable or improving margins · -5.6%Positive revenue growth · 38.4%Positive free cash flow · 0.71Manageable debt level · 0.38Healthy liquidity · 9.07

Analyst view

Analyst sentiment and price target

ANAB
Analyst sentiment
Based on 23 analyst votes · 2026-10-20
87/100
Bullish
Bullish
17
Hold
6
Bearish
0
Price Target
2026-09-25
Low
$70.00
Mean
$79.17
Median
$77.00
High
$95.00

Company Overview

IPO: 1/26/2017
Industry: Biotechnology
P/B i: 155.29
Debt / Equity i: 0.38
Operating Margin: 20.42%
Net Margin: -5.64%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.38
Current Ratio: 9.07
Quick Ratio: 9.07
Status: Good

Insider Transactions

Recent executive and insider activity

Orwin John A
Transaction: 09/15/2026
SELL
Change
-1,300
Price
Not reported
Filing
09/17/2026
Type
SELL
Orwin John A
Transaction: 09/15/2026
BUY
Change
+1,300
Price
Not reported
Filing
09/17/2026
Type
BUY
Faga Daniel
Transaction: 03/12/2026
BUY
Change
+53,334
Price
Not reported
Filing
08/07/2026
Type
BUY